Pathogenesis, diagnostics and therapy of COPD;Pathogenese, Diagnostik und Therapie der COPD

Pneumologie

Volumn 54, Issue 3, 2000, Pages 123-132

  Ullmer, E ^a   Soler M ^b   Hamm, H ^a   Perruchoud, André P ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; STEROID; THEOPHYLLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; FORCED EXPIRATORY VOLUME; HUMAN; PRIORITY JOURNAL; REVIEW;

BRONCHODILATOR AGENTS; EUROPE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PREVALENCE; STEROIDS;

EID: 0034005610     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9079     Document Type: Review

References (71)

1. 1 Anderson W, Wisniewski M, Barbee R, Rickard KA. Comparison of Serevent and ipratropium on pulmonary function in COPD patients reversible to ipratropium. Am J Respir Crit Care Med 1997; 155: A277
2. 1. The Lung Health Study. JAMA 1994; 272: 1497-1505
3. 3 ATS Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-120
4. 4 Barnes PJ. New therapies for chronic obstructive pulmonary disease. Thorax 1998; 53: 137-147
5. 5 Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-975
6. 6 Bloch KE. Lungenemphysem: Indikation zur chirurgischen Behandlung. Schweiz Med Wochenschr 1998; 128: 442-450
7. 7 Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 477-482
8. 8 Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-821
9. 9 Brändli O. Sind inhalierte Staubpartikel schädlich für unsere Lungen? Schweiz Med Wochenschr 1996; 126: 2165-2174
10. 10 Brian LT. Disease management of COPD with pulmonary rehabilitation. CHEST 1997; 112: 1630-1656
11. 11 British Thoracic Society Statement. COPD: summary of guidelines. Thorax 1997; 52 (Suppl 5): S2-21
12. 12 Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G et al.. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. NEJM 1995; 333: 817-822
13. 13 Büchi S, Villiger B, Sensky T, Schwarz F, Wolf Ch, Buddeberg C. Psychosocial predictors of long-term success of in-patient pulmonary rehabilitation of patients with COPD. Eur Respir J 1997; 10: 1272-1277
14. 14 Burge PS. EUROSCOP, ISOLDE and the Copenhagen city lung study. Thorax 1999; 54: 287-288
15. 15 Chambers DC, Tunnicliffe WS, Ayres JG. Acute inhalation of cigarette smoke increases lower respiratory tract nitric oxide concentrations. Thorax 1998; 53: 677-679
16. 16 Chanez P, Vignola AM, O'Shaugnessy R, Enander I, Li D, Jeffery PK, Bousquet J. Corticosteroid reversibility in COPD is related to features of asthma. Respir Crit Care Med 1997; 155: 1529-1534
17. 17 COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. CHEST 1994; 105: 1411-1419
18. 18 Confalonieri M, Mainardi E, Porta RD, Bernorio S, Bandola L, Beghè B, Spanevello A. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-585
19. 19 Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years observation on male British doctors. BMJ 1994; 309: 901-910
20. 20 Gosselink R, Troosters T, Decramer M. Exercise training in COPD patient: the basic questions. Eur Respir J 1997; 10: 2884-2891
21. 21 Hak E, Essen van GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? J Epidem and Community Health 1998; 52: 120-125
22. 22 Henningsfield JA. Nicotine medications for smoking cessation. N Engl J Med 1196-1203
23. 23 Hess Th. Pneumokokken-Impfung - Ja oder Nein? Schweiz Med Wochenschr 1096-1103
24. 24 Hillberg RE, Johnson DC. Noninvasive Ventilation. N Engl J Med 1997; 337: 1746-1752
25. 25 Hurt RD, Sachs DPL, Glover ED. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337
26. 26 Ingenito EP, Evans RB, Loring SJ, Kaczka DW, Rodenhouse JD, Body SC, Sugarbaker DJ, Mentzer SJ, DeCamp MM, Reilly JJ. Relation between preoperative inspiratory lung resistance and the outcome of lung-volume-reduction surgery for emphysema. N Engl J Med 1998; 338: 1181-1185
27. 27 Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129-136
28. 28 Joint ACCP/ACVPR Evidence-Based Guidelines:. Pulmonary Rehabilitation. CHEST 1997; 112: 1363-1396
29. 29 Jones PW, Bosh TK in association with an international study group. Quality of life changes in COPD patients treated with Salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289
30. 30 Keatings VM, Jatakanow A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548
31. 31 Köhler D, Criée C, Raschke F et al. Leitlinien zur häuslichen Sauerstoff-und Heimbeatmungstherapie. Med Klinik 1997; 92: 2-6
32. 32 Koyama H, Geddes DM. Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease. Thorax 1998; 53 (Suppl 2):S10-S14
33. 33 Langley SJ, Masterson CM, Batty EP, Woodcock A. Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo. Eur Respir J 1998; 11: 1081-1085
34. 34 Leuenberger P, Anderhub HP, Brändli O, Keller R, Knoblauch A, Kuhn M, Perruchoud AP, Rochat T, Russi E, Villinger B, Zellweger JP. Management 1997 of chronic obstructive pulmonary disease. Schweiz Med Wochenschr 1997; 127: 766-782
35. 35 Leuenberger P, Schwartz J, Ackermann-Liebrich U, Blaser K, Bolognini G et al. Passive Smoking Exposure in Adults and Chronic Respiratory Symptoms (SAPALDIA Study). Am J Resp Crit Care Med 1994; 150: 1221-1228
36. 36 Leuppi JD, Zenhäusern R, Schwarz F, Frey WO, Villiger B. Bedeutung der Trainingsintensität für die Verbesserung der Ausdauerleistungsfähigkeit bei Patienten mit chronisch obstruktiven Lungenerkrankungen. Dtsch Med Wschr 1998; 123: 174-178
37. 37 Llewellyn-Jones CG, Harris TAJ, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153: 616-621
38. 38 Lundback B, Lindstrom M, Jonsson E, Anderson S, van Herwaarden C. Effect of N-acetylcysteine on the decline in lung function in patients with COPD. Eur Respir J 1995; 5 (Suppl 15): 895
39. 39 Maesen FPV, Smeets JJ, Siedsens TJH, Wald FDM, Cornelissen PJG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1506-1513
40. 40 Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 998-1002
41. 41 McEvoy CE, Ensrud KE, Genant HK, Uy W, Griffith JM, Niewoehner DE. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 704-709
42. 42 McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. CHEST 1997; 111: 732-743
43. 43 Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 315: 773-780
44. 44 Pauwels RA, Löfdahl C-G, Laitinen LA, Scheuten JP, Postma DS et al. Longterm treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. NEJM 1999; 349: 1948-1953
45. 45 Perrin C, El Far Y, Vandenbos F, Tamisier R, Dumon MC, Lemoigne F, Mouroux J, Blaive B. Domiciliary nasal intermittent positive pressure ventilation in severe COPD: effects on lung function and quality of life. Eur Respir J 1997; 10: 2835-2839
46. 46 Petty TL. Supportive Therapy in COPD. CHEST 1998; 113: 256S-262S
47. 47 Rabe KF, Dent G, Magnussen H. Theophyllin und selektive Phosphodiesterase-Hemmer in der Therapie obstruktiver Atemwegserkrankungen. Pneumologie 1997; 51: 303-316
48. 48 Renkama TEJ, Schouten JP, Koëter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. CHEST 1996; 109: 1156-1162
49. 49 Rennard SI. Overview of definitions, epidemiology, and factors influencing its development. CHEST 1998; 113: 235-241S
50. 50 Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. CHEST 1996; 110: 62-70
51. 51 Repine JE, Bast A, Lankhorst I and The Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341-357
52. 52 Russi EW, Stammberger U, Weder W. Lung volume reduction surgery for emphysema. Eur Respir J 1997; 10: 208-218
53. 53 Sandford AJ, Weir TD, Paré PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1380-1391
54. 54 Sciurba FC, Rogers RM, Keenan RJ, Slivka WA, Gorcsan J, Ferson PF, Holbert M, Brown ML, Landreneau RJ. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996; 334: 1095-1099
55. 55 Senior MR, Anthonisen MR. Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1998; 157: S139-S147
56. 56 Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). ERS-consensus statement. Eur Respir J 1995; 8: 1398-1420
57. 57 Silverman EK, Chapman HR, Drazen JM, Weiss ST, Rosner B et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1770-1778
58. 58 Sivasothy P, Smith IE, Shneerson JM. Mask intermittent positive pressure ventilation in chronic hypercapnic respiratory failure due to chronic obstructive pulmonary disease. Eur J Respir 1998; 11: 34-40
59. 59 Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997; 350: 630-633
60. 60 Speich R, Boehler A, Weder W. Lungentransplantation bei fortgeschrittenem Lungenemphysem. Therapeutische Rundschau 1999; 56(3): 161-165
61. 61 Stammberger U, Bloch KE, Thurnheer R, Bingisser R, Weder W, Russi EW. Exercise performance and gas exchange after bilateral video-assisted thoracoscopic lung volume reduction for severe emphysema. Eur Respir J 1998; 12: 785-792
62. 62 Stanescu D, Sanna A, Veriter C, Robert A. Identification of smokers susceptible to development of chronic airflow limitation. A 13-year follow up. CHEST 1998; 114: 416-425
63. 63 Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-412
64. 64 Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N et al. Comparison of addition of theophylline to inhaled steroid with doubling the dose of inhaled steroid in asthma. Eur Respir J 1997; 10: 2754-2760
65. 65 Ullmer E, Bolliger CT. Tabak: Asche, Rauch und "Kohle". Schweiz Med Wochenschr 1999; 129: 102-112
66. 66 Ullmer E, Solèr M. Asthma und COPD: Unterschiede und Gemeinsamkeiten. Internist 1999; 40: 837-843
67. 67 Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823
68. 68 Wettengel R, Böhning W, Cegla U, Criée C, Fichter J et al. Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch obstructiver Bronchitis und Lungenemphysem. Med Klinik 1995; 90: 3-7
69. 69 Wilson R. The role of infection in COPD. CHEST 1998; 113: 242S-248S
70. 70 Zemp E, Elsasser S, Schindler Ch, Künzli N, Perruchoud AP et al. Long-Term Ambient Air Pollution and Respiratory Symptoms in Adults (SAPALDIA Study). Am J Respir Crit Care Med 1999; 159: 1257-1266
71. 71 Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients. A 6-year prospective study. CHEST 1998; 113: 65-70